References
- Fanin M, Nascimbeni AC, Fulizio L, et al. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord 2005; 15: 218–224
- Piluso G, Politano L, Aurino S, et al. Extensive scanning of thecalpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005; 42: 686–693
- Keira Y, Noguchi S, Minami N, et al. Localization of calpain 3 inhuman skeletal muscle and its alterations in limb-girdle muscular dystrophy 2A muscle. J Biochem 2003; 133: 659–664
- Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81: 27–40
- Sorimachi H, Kinbara K, Kimura S, et al. Muscle-specific calpain,p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995; 270: 31158–31162
- Baghdiguian S, Martin M, Richard I, et al. Calpain 3 deficiency isassociated with myonuclear apoptosis and profound perturbation of the IkBoc/NF-kB pathway in LGMD type 2A. Nat Med 1999; 5: 503–511
- Kramerova I, Kudryashova E, Venkatraman G, et al. Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum Mol Genet 2005; 14: 2125–2134
- Walton JN, Nattrass FJ. On the classification, natural history andtreatment of the myopathies. Brain 1954; 77: 169–231
- Fanin M, Fulizio L, Nascimbeni AC, et al. Molecular diagnosis inLGMD2A: Mutation analysis or protein testing? Hum Mut 2004; 24: 52–62
- Saenz A, Leturcq F, Cobo AM, et al. LGMD2A: Genotype-phenotype correlations based on a large mutational survey on the calpain-3 gene. Brain 2005; 128: 732–742
- Liu J, Aoki M, Ilia I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998; 20: 31–36
- Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003; 423: 168–172
- Mahjneh I, Passos-Bueno MR, Zatz M, et al. The phenotype of chromosome 2p-linked limb-girdle muscular dystrophy. Neuromuscul Disord 1996; 6: 483–490
- Bushby KMD. Making sense of the limb-girdle muscular dystrophies. Brain 1999; 122: 1403–1420
- Campanaro S, Romualdi C, Fanin M, et al. Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet 2002; 26: 3283–3298
- Fanin M, Pegoraro E, Matsuda-Asada C, et al. Calpain-3 and dysferlin protein screening in limb-girdle muscular dystrophy and myopathy patients. Neurology 2001; 56: 660–665
- Kawabe K, Goto K, Nishino I, et al. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol 2004; 11: 657–661
- Pollitt C, Anderson LV, Pogue R, et al. The phenotype of calpainopathy: Diagnosis based on a multidisciplinary approach. Neuromuscul Disord 2001; 11: 287–296
- Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy and atypical dysferlinopathies. Hum Mut 2005; 26: 165
- Borsato C, Padoan R, Stramare R, et al. Limb-girdle muscular dystrophies type 2A and 2B: Clinical and radiological aspects. Basic Appl Myol 2006; 16: 17–25
- Cenacchi G, Fanin M, Badiali de Giorgi L, et al. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005; 58: 190–195
- Bartoli M, Roudaut C, Martin S, et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb girdle muscular dystrophy type 2A. Mol Ther 2006; 13: 250–259
- Zaiss AK, Muruve DA: Immune response to adeno-associated virus vectors. Curr Gene Ther 2005; 5: 323–331
- Bartoli M, Poupiot J, Vulin A, et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 2007; 14: 733–740
- Wenzel K, Zabojszcza J, Carl M, et al. Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 2005; 175: 6219–6125